6505--Revlimid, Pomalyst, Camzyos Specialty Pharmaceuticals

The Department of Veterans Affairs Network Contracting Office 12 awarded a sole-source contract to Bristol-Myers Squibb Company for the procurement of specialty pharmaceuticals, specifically Revlimid, Pomalyst, and Camzyos. These medications are used to treat multiple myeloma, myelodysplastic syndromes, lymphoma, and obstructive hypertrophic cardiomyopathy for patients at the William S. Middleton Memorial VA Medical Center Specialty Pharmacy in Madison, Wisconsin. The total award amount is $848,445.00, executed under Federal Supply Schedule contract 36F79724D0101. The award date was December 31, 2025, with performance beginning approximately January 10, 2026. This procurement was conducted as a sole-source action due to strict FDA-mandated Risk Evaluation and Mitigation Strategy (REMS) program restrictions, which limit the distribution of these drugs to a closed network of certified specialty pharmacies that excludes VA facilities. Consequently, fulfillment is managed through CoverMyMeds (McKesson Specialty Pharmacy). The justification for bypassing full and open competition is based on the critical need to ensure uninterrupted, life-sustaining therapy for 14 active patients and the current lack of viable generic alternatives, with generic lenalidomide not expected to be consistently available until March 2026. The government will continue to monitor generic availability and explore REMS certification for VA pharmacies to reduce future sole-source dependency.